This article reviews the current data on human papillomavirus as the cause of most
cervical cancer cases, data on the recently approved human papillomavirus vaccines,
and updated information concerning the Bethesda System for interpretation of Papanicolaou
test results. Current recommendations for surgical treatment, concurrent chemotherapy,
and radiation therapy and recent advances in systemic therapy for advanced or metastatic
cervical cancer are reviewed.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Cancer statistics, 2006.CA Cancer J Clin. 2006; 56: 106-130
- Global cancer statistics, 2002.CA Cancer J Clin. 2005; 55: 74-108
- Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.JAMA. 2002; 288: 1749-1757
- Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med. 2003; 348: 518-527
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.Br J Cancer. 2003; 88: 63-73
- Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? a meta-analysis.Sex Transm Dis. 2002; 29: 725-735
- Condom use and the risk of genital human papillomavirus infection in young women.N Engl J Med. 2006; 354: 2645-2654
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.J Pathol. 1999; 189: 12-19
- Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.J Natl Cancer Inst. 1995; 87: 796-802
- Human papillomavirus oncogenesis.Clin Lab Med. 2000; 20: 383-406
- Human papillomavirus and cervical carcinogenesis.Best Pract Res Clin Obstet Gynaecol. 2001; 15: 663-676
- The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication.J Biol Chem. 1995; 270: 27283-27291
- Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning.Proc Natl Acad Sci U S A. 2004 Mar 23; 101 (Epub 2004 Mar 12.): 4030-4035
- Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.Proc Natl Acad Sci U S A. 1992; 89: 12180-12184
- A controlled trial of human papillomavirus type 16 vaccine.N Engl J Med. 2002; 347: 1645-1651
- Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.Lancet. 2006; 367: 1247-1255
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.Lancet Oncol. 2005; 6: 271-278
- Prophylactic human papillomavirus vaccines.J Clin Invest. 2006; 116: 1167-1173
- International incidence rates of invasive cervical cancer after introduction of cytological screening.Cancer Causes Control. 1997; 8: 755-763
- Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?.Obstet Gynecol. 2002; 99: 1053-1059
- Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.Obstet Gynecol. 2006; 107: 997-1005
- Screening for cervical cancer and initial treatment of patients with abnormal results from Papanicolaou testing.Mayo Clin Proc. 2005; 80: 1063-1068
- The 2001 Bethesda System: terminology for reporting results of cervical cytology.JAMA. 2002; 287: 2114-2119
- Natural history of cervicovaginal papillomavirus infection in young women.N Engl J Med. 1998; 338: 423-428
- Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.Lancet. 2001; 357: 1831-1836
- Natural history of dysplasia of the uterine cervix.J Natl Cancer Inst. 1999; 91: 252-258
- Human papillomavirus update with a particular focus on cervical disease.Pathology. 2002; 34: 213-224
- Progression and regression of cervical lesions: review of smears from women followed without initial biopsy or treatment.J Clin Pathol. 1980; 33: 517-522
- FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.Semin Surg Oncol. 1994; 10: 31-46
- Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women.J Gen Virol. 2005; 86: 2709-2720
- Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus.Obstet Gynecol. 1998; 91: 848-850
- HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data.Int J STD AIDS. 1999; 10: 795-802
- Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study.Cancer Causes Control. 2003; 14: 805-814
- International Federation of Gynecology and Obstetrics FIGO staging of gynecologic cancers: cervical and vulva.Int J Gynecol Cancer. 1995; 5: 319-324
- Cervix uteri.in: Greene FL Page DL Fleming ID AJCC Cancer Staging Handbook. 6th ed. Springer, New York, NY2002: 259-265
- Results on the treatment of uterine cervix cancer: ten years experience.Eur J Gynaecol Oncol. 2006; 27: 607-610
- A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study.Gynecol Oncol. 1999; 73: 177-183
- A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.Int J Radiat Oncol Biol Phys. 2006 May 1; 65 (Epub 2006 Jan 19.): 169-176
- Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma).Gynecol Oncol. 1989; 33: 265-272
- Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis: a Gynecologic Oncology Group study.Am J Obstet Gynecol. 1998; 178: 62-65
- Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer: a series of 50 pregnancies and review of the literature.Gynecol Oncol. 2005; 98: 3-10
- Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.J Clin Oncol. 2000; 18: 1606-1613
- Cervical cancer.NIH Consens Statement. 1996; 14: 1-38
- Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.Lancet. 2001; 358: 781-786
- Tumor and treatment factors improving outcome in stage III-B cervix cancer.Int J Radiat Oncol Biol Phys. 1991; 20: 95-100
- FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy.Int J Radiat Oncol Biol Phys. 1999; 43: 763-775
- The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix.Int J Radiat Oncol Biol Phys. 2002; 52: 33-48
- The hazard of accelerated tumor clonogen repopulation during radiotherapy.Acta Oncol. 1988; 27: 131-146
- The effect of treatment duration in the local control of cervix cancer.Radiother Oncol. 1992; 25: 273-279
- Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.Int J Radiat Oncol Biol Phys. 2002; 52: 1330-1337
- Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).Int J Radiat Oncol Biol Phys. 2007 Jun 1; 68 (Epub 2007 Mar 2.): 485-490
- Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.Int J Radiat Oncol Biol Phys. 2005 Nov 15; 63 (Epub 2005 Aug 15.): 1083-1092
- Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials.Eur J Cancer. 2003; 39: 2470-2486
- Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.Cancer. 1981; 48: 899-903
- Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.J Clin Oncol. 1985; 3: 1079-1085
- Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.J Clin Oncol. 1997; 15: 165-171
- Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.J Clin Oncol. 2004; 22: 3113-3119
- Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study.J Clin Oncol. 2005 Jul 20; 23 (Epub 2005 May 23.): 4626-4633
Article Info
Identification
Copyright
© 2007 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
